7 news items
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
AUPH
5 Jun 24
% of people with LN go untreated. Aurinia is committed to improving health outcomes for people living with LN by educating patients and providers
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024
AUPH
14 May 24
with LN go untreated. Aurinia is committed to improving health outcomes for people living with LN by educating patients and providers on the critical
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
AUPH
9 May 24
, research shows that approximately 50% of SLE patients are not screened for LN and 77% of people with LN go untreated. Aurinia is committed to improving
Aurinia Pharmaceuticals Shareholder Urges Board Of Directors To Take Action To Enhance Shareholder Value; Outlines Concerns Regarding The Company's Current Strategy And Board Composition And Offers Superior Paths To Improving Performance And Market Penetration
AUPH
7 May 24
for a reduced Board that is committed to effective market penetration strategies and shareholder value enhancement.We urge the Board to embrace
Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value
AUPH
7 May 24
(the "Annual Meeting") will serve as an opportunity for shareholders to vote for a reduced Board that is committed to effective market penetration
3p6bp m7vh
AUPH
2 May 24
and the urgent need for appropriate treatment. This momentum demonstrates our full commitment to solid execution and driving growth, as we continue in our work
wd7msb7i5rrhorbj8hb
AUPH
1 May 24
in all our efforts, and we remain committed to listening to their perspectives at every stage of our journey
- Prev
- 1
- Next